
AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo
The first patient has been dosed with AU-007 in a phase 2 cohort evaluating the drug in combination with the anti-PD-1 antibody Opdivo (nivolumab) and low-dose, subcutaneous aldesleukin for second-line treatment of melanoma, according to a news release …